Abstract
The catecholamine dopamine is a neurotransmitter involved in movement control; it is mainly produced in the adrenal glands and the brain. In the latter, a large number of dopaminergic neurons can be found in the substantia nigra pars compacta. The specific degeneration of neurons in the substantia nigra pars compacta causes rigidity, tremor, and bradykinesia, all of which are hallmark symptoms of Parkinson’s disease. One of the potential molecular factors that might induce the loss of dopaminergic neurons is an elevated level of reactive oxygen species which causes cell damage over time. Dopaminergic neurons are especially prone to ROS production, since dopamine, as well as its precursors and downstream metabolites, is readily oxidized enzymatically or via autoxidation. In this chapter we will describe how dopamine metabolism and reactive oxygen species are linked and show possible consequences of excessive ROS production and how dopaminergic neurons can react to this stress.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AADC:
-
Aromatic amino acid decarboxylase
- ALDH:
-
Aldehyde dehydrogenase
- ANLSH:
-
Astrocyte–neuron lactate shuttle hypothesis
- ApN:
-
Aminopeptidase N
- BBB:
-
Blood–brain barrier
- BH4:
-
Tetrahydrobiopterin
- CA:
-
Catecholamine
- COMT:
-
Catechol-O-methyltransferase
- DA:
-
Dopamine
- DAB:
-
Dopamine-beta-hydroxylase
- DAT:
-
Dopamine transporter
- DHPR:
-
Dihydropteridine reductase
- DOPAC:
-
3,4-Dihydroxyphenylacetic acid
- DOPAL:
-
3,4-Dihydroxyphenylaldehyde
- DOPET:
-
3,4-Dihydroxyphenylethanol
- DT Diaphorase:
-
NAD(P)H:quinone oxidoreductase
- E:
-
Epinephrine
- GPx:
-
Glutathione peroxidase
- GR:
-
Glutathione reductase
- GSH:
-
Reduced glutathione
- GSSG:
-
Oxidized glutathione
- HVA:
-
Homovanillic acid
- l-DOPA:
-
l-3,4-Dihydroxyphenylalanine
- MAO:
-
Monoamine oxidase
- MCT:
-
Monocarboxylate transporter
- NE:
-
Norepinephrine
- NM:
-
Neuromelanin
- NO:
-
Nitric oxide
- NOS:
-
Nitric oxide synthase
- PD:
-
Parkinson’s disease
- PNMT:
-
Phenylethanolamine-N-methyltransferase
- PST:
-
Phenylsulfotransferase
- PTP:
-
Permeability transition pore
- ROS:
-
Reactive oxygen species
- SN:
-
Substantia nigra
- SOD:
-
Superoxide dismutase
- TCA:
-
Tricarboxylic acid
- TH:
-
Tyrosine hydroxylase
- UGT:
-
Uridine diphosphoglucuronosyltransferases
- VMAT2:
-
Vesicular monoamine transporter 2
- Îł-GT:
-
Gamma-glutamyl transpeptidase
References
Carlsson, A.: The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11, 490–493 (1959)
Blaschko, H.: The specific action of L-dopa decarboxylase. J. Physiol. Lond. 96, 50–51 (1939)
Meiser, J., Weindl, D., Hiller, K.: Complexity of dopamine metabolism. Cell Commun. Signaling 11, 34 (2013)
Fitzpatrick, L.A., Calkins, E., Summerson, W.H.: Mammalian tyrosinase: melanin formation by ultraviolet irradiation. Arch. Dermatol. Syphilol. 59, 620–625 (1949)
Raper, H.S.: The tyrosinase-tyrosine reaction. Biochem. J. 21, 89–96 (1927)
Raper, H.S.: The aerobic oxidases. Physiol. Rev. 8, 245–282 (1928)
Rios, M., Habecker, B., Sasaoka, T., Eisenhofer, G., Tian, H., Landis, S., Chikaraishi, D., Roffler-Tarlov, S.: Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase. J. Neurosci. Off. J. Soc. Neurosci. 19, 3519–3526 (1999)
Bromek, E., Haduch, A., Gołembiowska, K., Daniel, W.A.: Cytochrome P450 mediates dopamine formation in the brain in vivo. J. Neurochem. 118, 806–815 (2011)
Eriksen, J., Jørgensen, T.N., Gether, U.: Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J. Neurochem. 113, 27–41 (2010)
Uutela, P., Karhu, L., Piepponen, P., Käenmäki, M., Ketola, R.A., Kostiainen, R.: Discovery of dopamine glucuronide in rat and mouse brain microdialysis samples using liquid chromatography tandem mass spectrometry. Anal. Chem. 81, 427–434 (2009)
Swahn, C.G., Wiesel, F.A.: Determination of conjugated monoamine metabolites in brain tissue. J. Neural Transm. 39, 281–290 (1976)
Männistö, P.T., Ulmanen, I., Lundström, K., Taskinen, J., Tenhunen, J., Tilgmann, C., Kaakkola, S.: Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 39, 291–350 (1992)
Tukey, R.H., Strassburg, C.P.: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581–616 (2000)
Alagarsamy, S., Phillips, M., Pappas, T., Johnson, K.M.: Dopamine neurotoxicity in cortical neurons. Drug Alcohol Depend. 48, 105–111 (1997)
Liu, Y., Edwards, R.H.: The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125–156 (1997)
Zucca, F.A., Basso, E., Cupaioli, F.A., Ferrari, E., Sulzer, D., Casella, L., Zecca, L.: Neuromelanin of the human substantia nigra: an update. Neurotox. Res. 25, 13–23 (2014)
Fenichel, G.M., Bazelon, M.: Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 18, 817–820 (1968)
Foley, J.M., Baxter, D.: On the nature of pigment granules in the cells of the locus coeruleus and substantia nigra. J. Neuropathol. Exp. Neurol. 17, 586–598 (1958)
Graham, D.G.: On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med. 103, 359–362 (1979)
Bazelon, M., Fenichel, G.M., Randall, J.: Studies on neuromelanin. I. A melanin system in the human adult brainstem. Neurology 17, 512–519 (1967)
Bogerts, B.: A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J. Comp. Neurol. 197, 63–80 (1981)
Cowen, D.: The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J. Neuropathol. Exp. Neurol. 45, 205–221 (1986)
Matzuk, M.M., Saper, C.B.: Preservation of hypothalamic dopaminergic neurons in Parkinson’s disease. Ann. Neurol. 18, 552–555 (1985)
Rosengren, E., Linder-Eliasson, E., Carlsson, A.: Detection of 5-S-cysteinyldopamine in human brain. J. Neural Transm. 63, 247–253 (1985)
Odh, G., Carstam, R., Paulson, J., Wittbjer, A., Rosengren, E., Rorsman, H.: Neuromelanin of the human substantia nigra: a mixed-type melanin. J. Neurochem. 62, 2030–2036 (1994)
Napolitano, A., Manini, P., d’Ischia, M.: Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr. Med. Chem. 18, 1832–1845 (2011)
Engelen, M., Vanna, R., Bellei, C., Zucca, F.A., Wakamatsu, K., Monzani, E., Ito, S., Casella, L., Zecca, L.: Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PLoS One 7, e48490 (2012)
Sulzer, D., Bogulavsky, J., Larsen, K.E., Behr, G., Karatekin, E., Kleinman, M.H., Turro, N., Krantz, D., Edwards, R.H., Greene, L.A., et al.: Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. 97, 11869–11874 (2000)
D’Amato, R.J., Lipman, Z.P., Snyder, S.H.: Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231, 987–989 (1986)
Lindquist, N.G., Larsson, B.S., Lydén-Sokolowski, A.: Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93, 1–6 (1988)
Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., Sabbioni, E.: Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 62, 1097–1101 (1994)
Zecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N.J., et al.: New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci. U. S. A. 105, 17567–17572 (2008)
Double, K.L., Gerlach, M., Schünemann, V., Trautwein, A.X., Zecca, L., Gallorini, M., Youdim, M.B.H., Riederer, P., Ben-Shachar, D.: Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66, 489–494 (2003)
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., Sarna, T.: Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. J. Neurochem. 106, 1866–1875 (2008)
Faucheux, B.A., Martin, M.-E., Beaumont, C., Hauw, J.-J., Agid, Y., Hirsch, E.C.: Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J. Neurochem. 86, 1142–1148 (2003)
Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G.P., Hebenstreit, G., Youdim, M.B.: Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199–205 (1988)
Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., Karluk, D.: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598–605 (1999)
McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G.: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38, 1285–1291 (1988)
Zhang, W., Zecca, L., Wilson, B., Ren, H.-W., Wang, Y.-J., Wang, X.-M., Hong, J.-S.: Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front. Biosci., Elite Ed. 5, 1–11 (2013)
Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., Lucius, R.: Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson’s disease. FASEB J. 17, 500–502 (2003)
McGeer, P.L., Schwab, C., Parent, A., Doudet, D.: Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54, 599–604 (2003)
Kim, W.G., Mohney, R.P., Wilson, B., Jeohn, G.H., Liu, B., Hong, J.S.: Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. Off. J. Soc. Neurosci. 20, 6309–6316 (2000)
Zecca, L., Zucca, F.A., Albertini, A., Rizzio, E., Fariello, R.G.: A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease. Neurology 67, S8–S11 (2006)
Gluck, M.R., Zeevalk, G.D.: Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson’s disease and catecholamine-associated diseases. J. Neurochem. 91, 788–795 (2004)
Cohen, G., Farooqui, R., Kesler, N.: Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U. S. A. 94, 4890–4894 (1997)
Kristal, B.S., Conway, A.D., Brown, A.M., Jain, J.C., Ulluci, P.A., Li, S.W., Burke, W.J.: Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30, 924–931 (2001)
Cohen, G., Kesler, N.: Monoamine oxidase and mitochondrial respiration. J. Neurochem. 73, 2310–2315 (1999)
Hauptmann, N., Grimsby, J., Shih, J.C., Cadenas, E.: The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch. Biochem. Biophys. 335, 295–304 (1996)
Ben-Shachar, D., Zuk, R., Glinka, Y.: Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64, 718–723 (1995)
Sherer, T.B., Betarbet, R., Testa, C.M., Seo, B.B., Richardson, J.R., Kim, J.H., Miller, G.W., Yagi, T., Matsuno-Yagi, A., Greenamyre, J.T.: Mechanism of toxicity in rotenone models of Parkinson’s disease. J. Neurosci. Off. J. Soc. Neurosci. 23, 10756–10764 (2003)
Panfili, E., Sandri, G., Ernster, L.: Distribution of glutathione peroxidases and glutathione reductase in rat brain mitochondria. FEBS Lett. 290, 35–37 (1991)
Berman, S.B., Hastings, T.G.: Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. J. Neurochem. 73, 1127–1137 (1999)
Zigmond, M.J., Hastings, T.G., Perez, R.G.: Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat. Disord. 8, 389–393 (2002)
Graumann, R., Paris, I., Martinez-Alvarado, P., Rumanque, P., Perez-Pastene, C., Cardenas, S.P., Marin, P., Diaz-Grez, F., Caviedes, R., Caviedes, P., et al.: Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson’s disease. Possible neuroprotective role of DT-diaphorase. Pol. J. Pharmacol. 54, 573–579 (2002)
Miyazaki, I., Asanuma, M.: Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med. Okayama 62, 141–150 (2008)
Smythies, J., Galzigna, L.: The oxidative metabolism of catecholamines in the brain: a review. Biochim. Biophys. Acta 1380, 159–162 (1998)
Nathan, C.: Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051–3064 (1992)
Graham, D.G.: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633–643 (1978)
Chesis, P.L., Levin, D.E., Smith, M.T., Ernster, L., Ames, B.N.: Mutagenicity of quinones: pathways of metabolic activation and detoxification. Proc. Natl. Acad. Sci. U. S. A. 81, 1696–1700 (1984)
Ross, D., Kepa, J.K., Winski, S.L., Beall, H.D., Anwar, A., Siegel, D.: NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129, 77–97 (2000)
Bindoli, A., Rigobello, M.P., Galzigna, L.: Toxicity of aminochromes. Toxicol. Lett. 48, 3–20 (1989)
Masoud, S.T., Vecchio, L.M., Bergeron, Y., Hossain, M.M., Nguyen, L.T., Bermejo, M.K., Kile, B., Sotnikova, T.D., Siesser, W.B., Gainetdinov, R.R., et al.: Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol. Dis. 74C, 66–75 (2014)
Imai, Y., Soda, M., Takahashi, R.: Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661–35664 (2000)
Kuhn, D.M., Francescutti-Verbeem, D.M., Thomas, D.M.: Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N. Y. Acad. Sci. 1074, 31–41 (2006)
Hauser, R.A.: Levodopa: past, present, and future. Eur. Neurol. 62, 1–8 (2009)
Przedborski, S., Jackson-Lewis, V., Muthane, U., Jiang, H., Ferreira, M., Naini, A.B., Fahn, S.: Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34, 715–723 (1993)
Rugbjerg, K., Friis, S., Lassen, C.F., Ritz, B., Olsen, J.H.: Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. Int. J. Cancer 131, 1904–1911 (2012)
Herrero Hernández, E.: Pigmentation genes link Parkinson’s disease to melanoma, opening a window on both etiologies. Med. Hypotheses 72, 280–284 (2009)
Wirdefeldt, K., Weibull, C.E., Chen, H., Kamel, F., Lundholm, C., Fang, F., Ye, W.: Parkinson’s disease and cancer: a register-based family study. Am. J. Epidemiol. 179, 85–94 (2014)
Ohshima, H., Tatemichi, M., Sawa, T.: Chemical basis of inflammation-induced carcinogenesis. Arch. Biochem. Biophys. 417, 3–11 (2003)
Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B.: Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49, 1603–1616 (2010)
Pfützner, W., Przybilla, B.: Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J. Am. Acad. Dermatol. 37, 332–336 (1997)
Rampen, F.H.: Levodopa and melanoma: three cases and review of literature. J. Neurol. Neurosurg. Psychiatry 48, 585–588 (1985)
Fiala, K.H., Whetteckey, J., Manyam, B.V.: Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat. Disord. 9, 321–327 (2003)
Olsen, J.H., Friis, S., Frederiksen, K.: Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17, 582–587 (2006)
Schulz, J.B., Lindenau, J., Seyfried, J., Dichgans, J.: Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267, 4904–4911 (2000)
Ricci, G., Volpi, L., Pasquali, L., Petrozzi, L., Siciliano, G.: Astrocyte-neuron interactions in neurological disorders. J. Biol. Phys. 35, 317–336 (2009)
Pellerin, L.: Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem. Int. 43, 331–338 (2003)
Pellerin, L., Pellegri, G., Bittar, P.G., Charnay, Y., Bouras, C., Martin, J.L., Stella, N., Magistretti, P.J.: Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev. Neurosci. 20, 291–299 (1998)
Kirchhoff, F., Dringen, R., Giaume, C.: Pathways of neuron-astrocyte interactions and their possible role in neuroprotection. Eur. Arch. Psychiatry Clin. Neurosci. 251, 159–169 (2001)
Dringen, R., Gutterer, J.M., Hirrlinger, J.: Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur. J. Biochem. 267, 4912–4916 (2000)
Hoffmann, G.F., Assmann, B., Bräutigam, C., Dionisi-Vici, C., Häussler, M., de Klerk, J.B.C., Naumann, M., Steenbergen-Spanjers, G.C.H., Strassburg, H.-M., Wevers, R.A.: Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann. Neurol. 54(Suppl 6), S56–S65 (2003)
Hyland, K.: Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J. Nutr. 137, 1568S–1572S (2007)
Coşkun, T., Karagöz, T., Kalkanoğlu, S., Tokatli, A., Ozalp, I., Thöny, B., Blau, N.: Guanosine triphosphate cyclohydrolase I deficiency: a rare cause of hyperphenylalaninemia. Turk. J. Pediatr. 41, 231–237 (1999)
Ritz, B.R., Manthripragada, A.D., Costello, S., Lincoln, S.J., Farrer, M.J., Cockburn, M., Bronstein, J.: Dopamine transporter genetic variants and pesticides in Parkinson’s disease. Environ. Health Perspect. 117, 964–969 (2009)
Javitch, J.A., D’Amato, R.J., Strittmatter, S.M., Snyder, S.H.: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82, 2173–2177 (1985)
Ransom, B.R., Kunis, D.M., Irwin, I., Langston, J.W.: Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci. Lett. 75, 323–328 (1987)
Radad, K., Rausch, W.-D., Gille, G.: Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem. Int. 49, 379–386 (2006)
Lee, D.-H., Lee, Y.J.: Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem. Toxicol. 49, 271–280 (2011)
Choi, W.-S., Kruse, S.E., Palmiter, R.D., Xia, Z.: Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. 105, 15136–15141 (2008)
Choi, W.-S., Palmiter, R.D., Xia, Z.: Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model. J. Cell Biol. 192, 873–882 (2011)
Ren, Y., Liu, W., Jiang, H., Jiang, Q., Feng, J.: Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280, 34105–34112 (2005)
Watabe, M., Nakaki, T.: Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J. Pharmacol. Exp. Ther. 323, 499–507 (2007)
Fitzmaurice, A.G., Rhodes, S.L., Lulla, A., Murphy, N.P., Lam, H.A., O’Donnell, K.C., Barnhill, L., Casida, J.E., Cockburn, M., Sagasti, A., et al.: Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 110, 636–641 (2013)
Funding
This project was supported by the Fonds National de la Recherche (FNR) Luxembourg (ATTRACT A10/03, THActivity CORE and AFR 5782260).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Delcambre, S., Nonnenmacher, Y., Hiller, K. (2016). Dopamine Metabolism and Reactive Oxygen Species Production. In: Buhlman, L. (eds) Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-42139-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-42139-1_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42137-7
Online ISBN: 978-3-319-42139-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)